In this paper recently published in Movement Disorders, Antonini et al., report the outcome of 10 clinical cases of Parkinson’s Disease patients infected by SARS-CoV-2, collected from the experience at the Parkinson and Movement Disorders Unit in Padua, Italy and the Parkinson’s Foundation Centre of Excellence at King’s College Hospital in London, UK. The results of the study suggest that PD patients of older age with longer disease duration are particularly susceptible to COVID-19 with a substantially high mortality rate (40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem specially vulnerable with a mortality rate of 50% among the four cases reported in the paper.
https://onlinelibrary.wiley.com/doi/10.1002/mds.28104
by Marialuisa Zedde and Francesco Cavallieri